Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 20/20 | 0.79 |
| ▸ | GUCY1A2 | P33402 | 20/20 | 0.79 |
| ▸ | GUCY1A1 | Q02108 | 20/20 | 0.79 |
| ▸ | GUCY1B1 | Q02153 | 20/20 | 0.79 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29831577 | 1.00 | GUCY1B2 (0.79) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL15087556 | 0.92 | GUCY1B2 (0.67) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL3439276 | 0.91 | GUCY1B2 (0.72) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL3437255 | 0.91 | GUCY1B2 (0.72) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL18405244 | 0.91 | GUCY1B2 (0.72) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL10269507 | 0.91 | GUCY1B2 (0.70) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL3437146 | 0.91 | GUCY1B2 (0.70) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL15069463 | 0.90 | GUCY1B2 (0.69) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL3436889 | 0.90 | GUCY1B2 (0.69) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL17307870 | 0.89 | GUCY1B2 (0.64) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103457-A1 | NOVEL PROCESS FOR PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250361228-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250255821-A1 | SOLID DISPERSIONS COMPRISING A SGC STIMULATOR | CYCLERION THERAPEUTICS, INC. | 2025-08-14 | — | — | US | disclosed |
| US-20250243177-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| EP-4570797-A2 | NOVEL PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| US-20250129060-A1 | SOLID FORMS OF AN SGC STIMULATOR | CYCLERION THERAPEUTICS INC (US) | 2025-04-24 | — | — | US | disclosed |
| US-12275724-B2 | Processes and intermediates for the preparation of soluble guanylate cyclase stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-12247025-B2 | Processes for preparation of soluble guanylate cyclase stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2025-03-11 | — | — | US | disclosed |
| US-20250017862-A1 | SOLID DISPERSIONS COMPRISING A SGC STIMULATOR | CYCLERION THERAPEUTICS INC (US) | 2025-01-16 | — | — | US | disclosed |
| US-20240391911-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2024-11-28 | — | — | US | disclosed |
| US-8748442-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748442-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| WO-2013101830-A1 | 2 - BENZYL, 3 - (PYRIMIDIN- 2 -YL) SUBSTITUTED PYRAZOLES USEFUL AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013101830-A1 | 2 - BENZYL, 3 - (PYRIMIDIN- 2 -YL) SUBSTITUTED PYRAZOLES USEFUL AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| EP-2588465-A1 | SGC STIMULATORS | Ironwood Pharmaceuticals, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20120184516-A1 | sGC Stimulators | CYCLERION THERAPEUTICS, INC. | 2012-07-19 | — | — | US | disclosed |
| US-20120184516-A1 | sGC Stimulators | CYCLERION THERAPEUTICS, INC. | 2012-07-19 | — | — | US | disclosed |
| US-20120184516-A1 | sGC Stimulators | CYCLERION THERAPEUTICS, INC. | 2012-07-19 | — | — | US | disclosed |
| WO-2012003405-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003405-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275724-B2 | Processes and intermediates for the preparation of soluble guanylate cyclase stimulators | GUCY1A2, GUCY1B1, GUCY1B2 | GUCY1B2 3/4885GUCY1A2 1/4885GUCY1A1 4/4885 |
| US-20120184516-A1 | sGC Stimulators | GUCY1A1, PTGIS, GUCY1B1 | GUCY1B2 6/4885GUCY1A2 4/4885GUCY1A1 1/4885 |
| US-12247025-B2 | Processes for preparation of soluble guanylate cyclase stimulators | GUCY1B1, GUCY1B2, GUCY1A2 | GUCY1B2 2/4885GUCY1A2 3/4885GUCY1A1 4/4885 |
| US-20250361228-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A2, GUCY1B1, GUCY1B2 | GUCY1B2 3/4885GUCY1A2 1/4885GUCY1A1 4/4885 |
| US-20250255821-A1 | SOLID DISPERSIONS COMPRISING A SGC STIMULATOR | GMPS, PRKG1, GUCY1A2 | GUCY1B2 10/4885GUCY1A2 3/4885GUCY1A1 6/4885 |
| US-20250129060-A1 | SOLID FORMS OF AN SGC STIMULATOR | GUCY1A2, PRKG1, GUCY1A1 | GUCY1B2 7/4885GUCY1A2 1/4885GUCY1A1 3/4885 |
| US-20250017862-A1 | SOLID DISPERSIONS COMPRISING A SGC STIMULATOR | GMPS, PRKG1, GUCY1A2 | GUCY1B2 10/4885GUCY1A2 3/4885GUCY1A1 6/4885 |
| US-20250243177-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | GUCY1B2 6/4885GUCY1A2 4/4885GUCY1A1 1/4885 |
| US-20240391911-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A2, GUCY1B1, GUCY1B2 | GUCY1B2 3/4885GUCY1A2 1/4885GUCY1A1 4/4885 |
| US-20260103457-A1 | NOVEL PROCESS FOR PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1B1, GUCY1B2, GUCY1A2 | GUCY1B2 2/4885GUCY1A2 3/4885GUCY1A1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.